- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Can Genomic Testing Help Offset Cancer Care Costs?
Emphasizing the importance of evaluating the big picture when it comes to diagnostic testing, David C. Collymore, MD, MBA, said, “When we think about genomic testing, and when we consider the total cost of care for oncology treatment, it may seem like it’s increasing the cost of care. But if we can get to a point where our outcomes are improved—although it may be a financial increase in terms of cost—if we can save lives, then the overall effect is positive.”
Rationalizing the expense that may be associated with diagnostic testing, Dr Collymore explained that it’s essential to move beyond the actual cost of care and start thinking about, “are we improving quality of life, are we saving lives, are we curing cancers…that really should be the focus,” he said.
“If done right, we will eventually get to a point where we’ll encounter cost savings. With genetic and genomic testing, if we can see a decrease in the incidence of cancer, it’s a tremendous cost saving,” said Dr Collymore. He strongly believes that even with an increase in the total cost of care per patient, if genomic testing can have an impact on the overall population, it will prove economically feasible for a healthcare system.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More
